公开(公告)号：US10077318B2

公开(公告)日：2018-09-18

申请号：US14851348

申请日：2015-09-11

Applicant: Genentech, Inc.

Inventor： Sunil Bhakta ,  Hans Erickson ,  Jagath R. Junutula ,  Katherine Kozak ,  Rachana Ohri ,  Thomas Pillow

IPC: C07K16/00 ,  C07K16/32 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K51/10 ,  C07K16/40 ,  G01N33/58 ,  A61K47/68 ,  A61K39/00

CPC classification number: C07K16/32 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6869 ,  A61K51/10 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/3069 ,  C07K16/3092 ,  C07K16/40 ,  C07K2317/40 ,  C07K2317/73 ,  C07K2317/94 ,  G01N33/582

Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.

公开(公告)号：US20230130874A1

公开(公告)日：2023-04-27

申请号：US17743727

申请日：2022-05-13

Applicant: Genentech, Inc.

Inventor： Sunil Bhakta ,  Hans Erickson ,  Jagath R. Junutula ,  Katherine Kozak ,  Rachana Ohri ,  Thomas Harden Pillow

IPC: C07K16/32 ,  A61K47/68 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K51/10 ,  C07K16/00 ,  C07K16/40 ,  G01N33/58

Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.

公开(公告)号：US20230341379A1

公开(公告)日：2023-10-26

申请号：US18188665

申请日：2023-03-23

Applicant: Genentech Inc.

Inventor： Katherine Kozak ,  Josefa dela Cruz Chuh

IPC: G01N33/50 ,  G01N33/58

CPC classification number: G01N33/505 ,  G01N33/5011 ,  G01N33/5038 ,  G01N33/582

Abstract: The present disclosure provides methods and systems for high throughput assays for testing immune cell engager molecules and potential immune cell engager molecules. In some embodiments, multiple parameters, for example, in connection with engagement of tumor cells by immune cells such as T cells and in connection with tumor cell death, may be analyzed from the same samples in the assays, and, in some cases, may be analyzed simultaneously. In some embodiments, the methods and systems allow for determining the kinetics of various parameters.